NTRA Today - Aug 12: Insider Moves and Trials

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

NTRA Today - Aug 12: Insider Moves and Trials

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly neighborhood investor, breaking down the day for you. Today, we’re talking about Natera, and it was a green day, up about 1%. Not a huge jump, but hey, green is good, right?

So, what went down? Natera had some exciting news today. They kicked off a trial for an immunotherapy treatment targeting skin cancers. This is a big deal because it’s not just about the stock; it’s about potentially helping a lot of people. Investors seemed to react positively to this news, and that helped keep the stock in the green.

Now, let’s talk about why things are buzzing. First off, there was a report on insider transactions. Some shares vested right before the company revealed a whopping 38% revenue surge. That definitely got people talking! When insiders are moving their shares, it usually raises eyebrows. Plus, Guggenheim raised their price target for Natera to $360. That’s a solid boost of confidence, and it’s got folks feeling optimistic.

Oh, and there’s also a partnership with Kupando for that cancer trial in Germany. Expanding into new markets and therapies is always a good look for a biotech company.

Looking ahead, it’s clear Natera’s got its eyes on growth, especially in the oncology space. That’s something to keep an eye on if you’re following this stock.

So, to wrap it up, Natera’s been making moves today with some promising news in the cancer treatment arena and solid support from insiders. Always interesting to see how these developments play out. Just remember, this is all for fun and info – no financial advice here! Catch you later!

まだレビューはありません